Q3 2025 Lifecore Biomedical Inc Earnings Call Transcript
Key Points
- Lifecore Biomedical Inc (LFCR) signed multiple new agreements with both new and existing customers, indicating strong business development.
- The company reported a 2% increase in revenues for the nine months ended February 23, 2025, driven by increased demand for hyaluronic acid manufacturing.
- Lifecore Biomedical Inc (LFCR) added six new customers during the first nine months of fiscal 2025, including a significant agreement with Nirsum Laboratories.
- The company is making progress in its late-stage pipeline, with several programs poised for potential FDA approval and commercialization by 2028.
- Operational efficiencies have improved, with better coordination between supply chain and operations teams, leading to increased productivity and reduced waste.
- Revenues for the third quarter decreased by 2% compared to the prior year, primarily due to a decrease in CDMO revenues.
- Gross profit for the third quarter declined by $2 million, mainly due to lower development revenue and inventory adjustments.
- The company recorded a net loss of $14.8 million for the third quarter, compared to net income in the same period last year.
- Selling, general, and administrative expenses increased due to litigation expenses and legacy legal matters.
- Adjusted EBITDA for the third quarter decreased by $0.7 million compared to the prior year period, reflecting lower gross profit.
Good afternoon and thank you for joining Lifecore's fiscal 2025 third quarter earnings call. During the call, all participants will be in a listen-only mode.
Now, I would like to turn the call over to Stephanie Diaz, the Manager of Investor Relations for Lifecore.
Good afternoon and thank you for joining us today to discuss Lifecore Biomedical's third quarter fiscal 2025 earnings results. Hosting the call today from Lifecore are Paul Josephs, President and Chief Executive Officer and Ryan Lake, Chief Financial Officer.
Before we begin today, we'd like to remind everyone that certain statements made in the course of this conference call contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, April 3, 2025, and the company's actual results could differ materially from those projected in such forward-looking statements.
For a more thorough
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
